Big pharmaceutical companies such as Merck, Eli Lilly and Johnson & Johnson are now counting on China and India for advanced research and development, new study shows.
Cost pressures, the need to tap global talent, and growth opportunities in emerging markets have already led western pharmaceutical companies to shift substantial manufacturing and clinical-trial work to Asia.
It now turns out that Indian and Chinese scientists are rapidly developing the ability to innovate and create their own intellectual property as a result of the movement of research and development (R&D) to their countries.
Several firms in these countries are performing advanced R&D and are moving into the highest-value segments of the pharmaceutical global value chain, says a study by sponsored by the Ewing Marion Kauffman Foundation on the globalization of the pharmaceutical industry shows, according to a press release from the foundation.
In 2006, 5.5 percent of all global pharmaceutical patent applications (WIPO PCT applications) named one inventor or more located in India, and 8.4 percent named one or more located in China. This had increased fourfold from 1995.
"Globalization is happening faster than people think. Having India and China conduct such sophisticated research and participate in drug discovery was unimaginable even five years ago," said Vivek Wadhwa, executive in residence at Duke University and a fellow at the Labor and Worklife Program of Harvard Law School, who led the team of researchers conducting the study. "The challenge is for America to understand this trend and realize the potential of globalization."
udhay saxena (MIT)